Speakers
Programmed at NextGen, in alphabetical order.
Sponsors
The companies behind the program. Tiers as disclosed.
Agenda
Selected from 11 sessions.
- Monday15June11:40 - 12:05TRACK 3
Chemical Space Generation, Exploration & Visualisation
The size of the virtually explorable chemical space is expanding due to the application of novel digital workflows. Effective selection of quality monomers, scalable information en…
- Tuesday16June09:00 - 09:25KEYNOTE
Designing Impactful Cancer Drugs
Small molecule therapeutics continue to form the backbone of therapies for all types of life-threatening diseases. The last decade has seen considerable progress in delivering prec…
- Tuesday16June09:25 - 09:50TRACK 3
Futures Of Small Molecule Discovery
• This presentation will outline four alternative future scenarios for synthetic origin molecule research. • It will describe a breakthrough scenario enabling rapid druggability of…
- Tuesday16June09:50 - 10:15TRACK 4
Beyond Binding: Functional ADC Safety Profiling with iPSC-Derived Human Tissues
- Tuesday16June11:15 - 11:40TRACK 3
From Structure To Degradation: Rethinking End-To-End Discovery Of Degraders And Molecular Glues
Overview of WuXi Biology’s integrated early-stage drug discovery platform for the identification of degraders and molecular glues, showcasing our expertise and capabilities across …
- Tuesday16June11:40 - 12:05TRACK 3
Drugging The Undruggables: TPD Approaches
- Tuesday16June12:30 - 12:55TRACK 4
Moving Toward A Definition For Neuroinflammation
• Exploring what we really mean by neuroinflammation • Highlighting key cellular and immune features involved in brain inflammation • Considering how clearer definitions could guid…
- Tuesday16June14:00 - 14:50TRACK 1
From Data Readiness to AI Value: Practitioner Insights Across the Drug Development Pipeline
• The value of connected systems • Data readiness as the foundation for impact-generating AI. • Prerequisites, hidden roadblocks, and incentive traps that decide whether AI initiat…
- Tuesday16June14:25 - 14:50TRACK 2
Leveraging Affinity Screening For HIT Discovery
Emerging modalities and genetics driven target selection have reshaped our early discovery portfolio whilst business pressures insist on cycle time compression. AstraZeneca’s respo…
An audience of 98 companies, parsed from the program.
98 companies in attendance.
The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.